Physician profile
Fred Woolley Stelson
NPI 1275718553
$7,114.92
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $856 · 2020: $84.30 · 2021: $1,630 · 2022: $1,220 · 2023: $1,670 · 2024: $1,654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,324.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Validus Pharmaceuticals LLC | $1,193.67 | 2019-2024 | Equetro |
| Otsuka America Pharmaceutical, INC. | $707.69 | 2019-2024 | Rexulti, Abilify Maintena, Abilify Mycite |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $636.85 | 2021-2024 | Caplyta |
| Corium, LLC | $529.46 | 2022-2024 | Azstarys |
| Neurocrine Biosciences, INC. | $500.38 | 2019-2024 | Ingrezza |
| Lundbeck LLC | $413.98 | 2019-2024 | Rexulti, Brintellix |
| Abbvie INC. | $410.17 | 2021-2024 | Vraylar |
| Alkermes, INC. | $394.94 | 2021-2024 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $338.56 | 2019-2024 | Trintellix |
| Ironshore Pharmaceuticals INC. | $276.76 | 2019-2024 | Jornay Pm |
| Axsome Therapeutics, INC. | $266.35 | 2023-2024 | Auvelity |
| Bausch Health US, LLC | $248.84 | 2019-2024 | Aplenzin, Wellbutrin |
| Almatica Pharma LLC | $245.94 | 2021-2024 | Loreev Xr, Sertraline Hcl |
| Allergan, INC. | $144.52 | 2019 | |
| Supernus Pharmaceuticals, INC. | $126.11 | 2021-2024 | Qelbree, Qelbree |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $119.45 | 2019-2024 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $95.02 | 2019-2024 | Spravato |
| Idorsia Pharmaceuticals US INC | $89.53 | 2022-2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $88.01 | 2023-2024 | Uzedy |
| Neos Therapeutics, LP | $81.01 | 2019 | |
| Avanir Pharmaceuticals, INC. | $55.06 | 2019-2021 | |
| Eisai INC. | $30.45 | 2021 | |
| Noven Therapeutics, LLC | $29.10 | 2024 | Xelstrym |
| Vanda Pharmaceuticals INC. | $27.03 | 2024 | Hetlioz, Fanapt |
| Biohaven Pharmaceuticals, INC. | $19.23 | 2021 | |
| Vertical Pharmaceuticals, LLC | $17.58 | 2024 | Relexxii |
| Jazz Pharmaceuticals INC. | $14.92 | 2021 | |
| Indivior INC. | $14.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fred Stelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.